<DOC>
	<DOCNO>NCT02655913</DOCNO>
	<brief_summary>This trial study efficacy safety combination vitamin C infusion modulate electro-hyperthermia ( mEHT ) treatment non small cell lung cancer patients.Phase I clinical study find tolerable dose best schedule combination vitamin C infusion mEHT give patient NSCLC . Phase II study learn combination vitamin C infusion mEHT help control NSCLC improve quality life .</brief_summary>
	<brief_title>Safety Efficacy Vitamin C Infusion Combination With Local mEHT Treat Non Small Cell Lung Cancer</brief_title>
	<detailed_description>Phase I Phase II clinical trial indicate large dose vitC infusion safe reduce toxic side effect chemo drug use synergy chemotherapy . The new technology modulate electro-hyperthermia ( mEHT ) , trade name : oncothermia proven efficacy lung cancer minimal side effects.The investigator accumulate successful case treatment primary lung cancer use vitamin C infusion combination oncothermia . One diagnose squamous cell lung cancer patient survive beyond 5 year receive intravenous vitamin C+ mEHT . Based , necessary conduct in-depth study explore best treatment protocol NSCLC patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Inclusion criterion : 18 year old 70 year Primary non small cell lung cancer ( stage 3 4 ) Subjects must last cancer therapy least four week prior entry study The patient must willing able sign inform consent prior start trial Candidates currently receive cancer therapy ( chemotherapy , molecular target drug therapy , radiation therapy ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Willingness comply weekly phone call office visit Patients must able take food orally peg tube feed Life expectancy least 6 month Lung metastasis/not primary non small cell lung cancer Glucose6phosphate dehydrogenase deficiency ( G6PD ) Vitamin C allergy Impossibility place patient mEHT machine Metallic implant replacement treatment area Electronic implant device anywhere Missing damage heatsense nerve fieldsensitive issue treatment area Comorbid condition affect survival : end stage congestive heart failure , unstable angina , myocardial infarction ( within past 6 week ) , uncontrolled blood sugar great 300 mg/dL , know chronic active hepatitis cirrhosis Renal insufficiency evidence serum creatinine â‰¥ 1.3mg/dl evidence oxalosis urinalysis Chronic hemodialysis Iron overload ( ferritin &gt; 500 ng/ml ) Wilson 's disease Compromised liver function evidence complete biliary obstruction serum bilirubin 2.0 liver function test ( AST &gt; 63 , ALT &gt; 95 ) exceed 1.5 x upper limit normal Very low white blood cell count ( &lt; 1.5 x 10 ( 9 ) /L ) , agranulocytosis ( &lt; 0.5 x 10 ( 9 ) /L ) severe anemia Pregnant lactate female Current tobacco use Evidence significant psychiatric disorder history examination would prevent completion study preclude inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Sodium ascorbate</keyword>
	<keyword>Non-Small-Cell Lung cancer</keyword>
	<keyword>Oncothermia</keyword>
	<keyword>Immune function</keyword>
	<keyword>Life quality</keyword>
	<keyword>Tumor marker</keyword>
	<keyword>Survival time</keyword>
</DOC>